

Francesco Marampon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2676307/publications.pdf>

Version: 2024-02-01

84
papers

2,631
citations

136740

32
h-index

223531

46
g-index

86
all docs

86
docs citations

86
times ranked

4599
citing authors

#	ARTICLE	IF	CITATIONS
1	Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. <i>Molecular Cancer</i> , 2006, 5, 31.	7.9	129
2	Vitamin D Protects Human Endothelial Cells from H2O2 Oxidant Injury Through the Mek/Erk-Sirt1 Axis Activation. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 221-231.	1.1	119
3	Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. <i>Molecular Cancer</i> , 2010, 9, 305.	7.9	113
4	MEK/ERK inhibitor U0126 affects <i>in vitro</i> and <i>in vivo</i> growth of embryonal rhabdomyosarcoma. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 543-551.	1.9	89
5	Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. <i>Cell Cycle</i> , 2008, 7, 1870-1879.	1.3	81
6	A feasibility study of percutaneous radiofrequency ablation followed by radiotherapy in the management of painful osteolytic bone metastases. <i>European Radiology</i> , 2011, 21, 2004-2010.	2.3	81
7	MEK/ERK Inhibitor U0126 Increases the Radiosensitivity of Rhabdomyosarcoma Cells <i>In vitro</i> and <i>In vivo</i> by Downregulating Growth and DNA Repair Signals. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 159-168.	1.9	78
8	Key role of MEK/ERK pathway in sustaining tumorigenicity and <i>in vitro</i> radioresistance of embryonal rhabdomyosarcoma stem-like cell population. <i>Molecular Cancer</i> , 2016, 15, 16.	7.9	75
9	HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells. <i>Cancer Letters</i> , 2017, 397, 1-11.	3.2	72
10	Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1 α functional interplay. <i>International Journal of Oncology</i> , 2014, 44, 2121-2131.	1.4	64
11	p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells. <i>Molecular Cancer</i> , 2005, 4, 41.	7.9	63
12	The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 5.	6.9	56
13	Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1717-1730.	1.2	56
14	Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells. <i>Oncology Reports</i> , 2013, 29, 1189-1195.	1.2	55
15	Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage. <i>Oncotarget</i> , 2016, 7, 5383-5400.	0.8	53
16	KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models. <i>BMC Cancer</i> , 2015, 15, 941.	1.1	50
17	Hormonal Therapy Promotes Hormone-Resistant Phenotype by Increasing DNMT Activity and Expression in Prostate Cancer Models. <i>Endocrinology</i> , 2011, 152, 4550-4561.	1.4	48
18	Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2530.	1.8	47

#	ARTICLE	IF	CITATIONS
19	ROCK2 and Its Alternatively Spliced Isoform ROCK2m Positively Control the Maturation of the Myogenic Program. <i>Molecular and Cellular Biology</i> , 2007, 27, 6163-6176.	1.1	46
20	Nerve Growth Factor Regulation of Cyclin D1 in PC12 Cells through a p21 ^{RAS} Extracellular Signal-regulated Kinase Pathway Requires Cooperative Interactions between Sp1 and Nuclear Factor- κ B. <i>Molecular Biology of the Cell</i> , 2008, 19, 2566-2578.	0.9	44
21	The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models. <i>Tumor Biology</i> , 2017, 39, 101042831769552.	0.8	44
22	PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer. <i>Endocrine-Related Cancer</i> , 2013, 20, 321-337.	1.6	43
23	Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines. <i>International Journal of Oncology</i> , 2014, 44, 285-294.	1.4	43
24	Treatment of Solitary Painful Osseous Metastases with Radiotherapy, Cryoablation or Combined Therapy: Propensity Matching Analysis in 175 Patients. <i>PLoS ONE</i> , 2015, 10, e0129021.	1.1	42
25	The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models. <i>Cancers</i> , 2019, 11, 359.	1.7	42
26	5 α - α zacididine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. <i>Prostate</i> , 2010, 70, 1166-1178.	1.2	41
27	Angiotensin-converting-enzyme inhibition counteracts angiotensin II-mediated endothelial cell dysfunction by modulating the p38/SirT1 axis. <i>Journal of Hypertension</i> , 2013, 31, 1972-1983.	0.3	41
28	Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1685-1699.	1.2	40
29	DNMT3B <i>in vitro</i> knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation. <i>Oncotarget</i> , 2016, 7, 79342-79356.	0.8	37
30	The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells. <i>Endocrine-Related Cancer</i> , 2011, 18, 385-400.	1.6	35
31	Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models. <i>Prostate</i> , 2014, 74, 852-868.	1.2	35
32	Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples. <i>International Journal of Oncology</i> , 2013, 42, 2116-2122.	1.4	33
33	The First Negative Allosteric Modulator for Dopamine D ₂ and D ₃ Receptors, SB269652 May Lead to a New Generation of Antipsychotic Drugs. <i>Molecular Pharmacology</i> , 2017, 91, 586-594.	1.0	33
34	Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells. <i>Journal of Hematology and Oncology</i> , 2017, 10, 161.	6.9	29
35	NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 881-893.	1.2	28
36	Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models. <i>International Journal of Oncology</i> , 2011, 40, 711-20.	1.4	27

#	ARTICLE	IF	CITATIONS
37	Locally Advanced Rectal Cancer: Treatment Approach in Elderly Patients. Current Treatment Options in Oncology, 2020, 21, 1.	1.3	27
38	Defective DNA repair mechanisms in prostate cancer: impact of olaparib. Drug Design, Development and Therapy, 2017, Volume11, 547-552.	2.0	26
39	Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 393-409.	1.2	25
40	PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines. Journal of Cancer Research and Clinical Oncology, 2019, 145, 137-152.	1.2	25
41	The possible prognostic role of histone deacetylase and transforming growth factor β /Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical study. European Journal of Histochemistry, 2017, 61, 2732.	0.6	24
42	The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. Journal of Hematology and Oncology, 2018, 11, 32.	6.9	24
43	Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models. Tumor Biology, 2016, 37, 341-351.	0.8	22
44	Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines. Cancer Letters, 2019, 461, 90-101.	3.2	22
45	Caveolin-1 promotes radioresistance in rhabdomyosarcoma through increased oxidative stress protection and DNA repair. Cancer Letters, 2021, 505, 1-12.	3.2	21
46	Clinically relevant radioresistant rhabdomyosarcoma cell lines: functional, molecular and immune-related characterization. Journal of Biomedical Science, 2020, 27, 90.	2.6	18
47	Caveolin-1 enhances metastasis formation in a human model of embryonal rhabdomyosarcoma through Erk signaling cooperation. Cancer Letters, 2019, 449, 135-144.	3.2	17
48	The Botanical Drug PBI-05204, a Supercritical CO2 Extract of Nerium Oleander, Inhibits Growth of Human Glioblastoma, Reduces Akt/mTOR Activities, and Modulates GSC Cell-Renewal Properties. Frontiers in Pharmacology, 2020, 11, 552428.	1.6	17
49	Neurotoxic and Neuroprotective Role of Exosomes in Parkinson's Disease. Current Pharmaceutical Design, 2020, 25, 4510-4522.	0.9	17
50	Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer. Oncotarget, 2017, 8, 111225-111245.	0.8	16
51	HDAC inhibition is associated to valproic acid induction of early megakaryocytic markers. Experimental Cell Research, 2006, 312, 1590-1597.	1.2	15
52	Cellular and Molecular Mediators of Bone Metastatic Lesions. International Journal of Molecular Sciences, 2018, 19, 1709.	1.8	15
53	BET inhibition therapy counteracts cancer cell survival, clonogenic potential and radioresistance mechanisms in rhabdomyosarcoma cells. Cancer Letters, 2020, 479, 71-88.	3.2	15
54	MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells. International Journal of Molecular Sciences, 2021, 22, 10671.	1.8	14

#	ARTICLE	IF	CITATIONS
55	Treatment of osteolytic solitary painful osseous metastases with radiofrequency ablation or cryoablation: A retrospective study by propensity analysis. <i>Oncology Letters</i> , 2016, 11, 1948-1954.	0.8	13
56	A New Threat to Dopamine Neurons: The Downside of Artificial Light. <i>Neuroscience</i> , 2020, 432, 216-228.	1.1	13
57	Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in <i>Avitro</i> and <i>in Vivo</i> , the alveolar phenotype subtype. <i>International Journal of Radiation Biology</i> , 2021, 97, 943-957.	1.0	13
58	Oral Platelet Gel Supernatant Plus Supportive Medical Treatment Versus Supportive Medical Treatment in the Management of Radiation-induced Oral Mucositis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 336-341.	0.6	12
59	Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models. <i>Oncotarget</i> , 2017, 8, 29865-29886.	0.8	12
60	Modulating the dose-rate differently affects the responsiveness of human epithelial prostate- and mesenchymal rhabdomyosarcoma-cancer cell line to radiation. <i>International Journal of Radiation Biology</i> , 2020, 96, 823-835.	1.0	12
61	The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models. <i>Cancers</i> , 2019, 11, 1604.	1.7	11
62	Radiation therapy and serum salivary amylase in head and neck cancer. <i>Oncotarget</i> , 2017, 8, 90496-90500.	0.8	10
63	Parkinson's disease and light: The bright and the Dark sides. <i>Brain Research Bulletin</i> , 2019, 150, 290-296.	1.4	10
64	The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review. <i>Journal of Contemporary Brachytherapy</i> , 2020, 12, 61-66.	0.4	10
65	ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma. <i>Cancers</i> , 2022, 14, 289.	1.7	10
66	Intravesical instillations with polydeoxyribonucleotides reduce symptoms of radiation-induced cystitis in patients treated with radiotherapy for pelvic cancer: a pilot study. <i>Supportive Care in Cancer</i> , 2014, 22, 1155-1159.	1.0	9
67	Increased expression and activity of p75 ^{NTR} are crucial events in azacitidine-induced cell death in prostate cancer. <i>Oncology Reports</i> , 2016, 36, 125-130.	1.2	9
68	Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell Lines <i>in Vitro</i> and <i>in Vivo</i> . <i>Journal of Oncology</i> , 2020, 2020, 1-16.	0.6	9
69	Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2894.	1.8	9
70	Adjuvant radiation therapy in stage I seminoma: 20 years of oncologic results. <i>Oncotarget</i> , 2016, 7, 80077-80082.	0.8	9
71	Antitumor effects of carnitinib in castration resistant prostate cancer models: A comparative study with erlotinib. <i>Prostate</i> , 2011, 71, 1481-1491.	1.2	8
72	OTX015 Epi-Drug Exerts Antitumor Effects in Ovarian Cancer Cells by Blocking GNL3-Mediated Radioresistance Mechanisms: Cellular, Molecular and Computational Evidence. <i>Cancers</i> , 2021, 13, 1519.	1.7	7

#	ARTICLE	IF	CITATIONS
73	Sildenafil Counteracts the In Vitro Activation of CXCL-9, CXCL-10 and CXCL-11/CXCR3 Axis Induced by Reactive Oxygen Species in Scleroderma Fibroblasts. <i>Biology</i> , 2021, 10, 491.	1.3	7
74	Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pARser81 and CDK1 signaling: biological implications for men treated with testosterone replacement therapy. <i>Oncotarget</i> , 2017, 8, 113792-113806.	0.8	7
75	The Botanical Drug PBI-05204, a Supercritical CO2 Extract of Nerium Oleander, Is Synergistic With Radiotherapy in Models of Human Glioblastoma. <i>Frontiers in Pharmacology</i> , 2022, 13, 852941.	1.6	7
76	Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II study. <i>Oncotarget</i> , 2018, 9, 33702-33709.	0.8	6
77	Testosterone-mediated activation of androgenic signalling sustains in vitro the transformed and radioresistant phenotype of rhabdomyosarcoma cell lines. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 183-197.	1.8	5
78	One-week vaginal brachytherapy schedule as exclusive adjuvant post-operative treatment in intermediate- and high-intermediate-risk endometrial cancer patients. <i>Journal of Contemporary Brachytherapy</i> , 2020, 12, 124-130.	0.4	5
79	MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression. <i>Frontiers in Oncology</i> , 2022, 12, 835642.	1.3	5
80	Recommendation for the contouring of limbic system in patients receiving radiation treatment: A pictorial review for the everyday practice and education. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103229.	2.0	4
81	Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma. <i>Pharmaceutics</i> , 2021, 14, 1082.	1.7	4
82	Hypofractionated intensity-modulated radiotherapy in locally advanced unresectable pancreatic cancer: A pilot study. <i>Current Problems in Cancer</i> , 2019, 43, 495-503.	1.0	3
83	Topical application of platelet supernatant gel in the management of radiotherapy-induced mucositis: a case report. <i>Blood Transfusion</i> , 2014, 12, 107-10.	0.3	3
84	Are we ready for a paradigm shift from high-dose conventional to moderate hypofractionated radiotherapy in intermediate-high risk prostate cancer? A systematic review of randomized controlled trials with trial sequential analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 75-82.	2.0	2